Amicus Therapeutics, Inc. provided earnings guidance for the year 2024. For the full-year 2024, the company anticipates total Galafold revenue growth between 11% and 16% at CER.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.195 USD | +1.71% | -12.14% | -35.48% |
01:24pm | Guggenheim Upgrades Amicus Therapeutics to Buy From Neutral With $13 Price Target | MT |
05-10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.48% | 2.68B | |
+30.39% | 48.16B | |
-0.65% | 41.73B | |
+43.79% | 41.03B | |
-5.31% | 28.77B | |
+10.48% | 25.59B | |
-22.49% | 18.96B | |
+9.16% | 12.92B | |
+28.71% | 12.03B | |
-2.27% | 11.77B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024